A European Commission official criticized a US investigation into pharmaceutical imports, viewing it as a potential precursor to tariffs that could negatively impact healthcare systems in both Europe and the US. The investigation, initiated by the Trump administration, raises concerns among pharmaceutical companies about rising drug prices and supply chain disruptions, particularly affecting countries like Ireland. The EU warns that tariffs could undermine access to critical medications and increase healthcare costs. A report estimates that a 25% tariff could raise US drug costs by nearly $51 billion annually. Teljes cikk (Euronews.com)